Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;3(1):1-3.
doi: 10.1016/j.bsheal.2020.11.007. Epub 2020 Dec 1.

The COVID-19 pandemics and the relevance of biosafety facilities for metagenomics surveillance, structured disease prevention and control

Thiago Moreno L Souza  1 , Carlos Medicis Morel  1
Affiliations

The COVID-19 pandemics and the relevance of biosafety facilities for metagenomics surveillance, structured disease prevention and control

Thiago Moreno L Souza et al. Biosaf Health. 2021 Feb.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic represents an enormous challenge to all countries, regardless of their development status. The manipulation of its etiologic agent SARS-CoV-2 requires a biosafety containment level 3 laboratories (BSL-3) to understand virus biology and in vivo pathogenesis as well as the translation of new knowledge into the preclinical development of vaccines and antivirals. As such, BSL-3 facilities should be considered an integral part of any public health response to emerging infectious disease prevention, control and management. Differently from BSL-2, BSL-3 units vary considerably along the range from industrialized to the least developed countries. Innovative Developing Countries (IDCs) such as Brazil, which excelled at controlling the 2015-2017 Zika epidemic, had to face a serious flaw in its disease control and prevention structure: the scarcity and uneven geographic distribution of its BSL-3 facilities, including those for preclinical animal experimentation.

Keywords: Biosafety facilities; COVID-19; Innovative Developing Countries (IDCs); Metagenomics surveillance; SARS-CoV-2.

PubMed Disclaimer

References

    1. Vasconcellos A.G., Fonseca B. de P.F. e, Morel C.M. Revisiting the concept of Innovative Developing Countries (IDCs) for its relevance to health innovation and neglected tropical diseases and for the prevention and control of epidemics. PLoS Negl. Trop. Dis. 2018;12 doi: 10.1371/journal.pntd.0006469. - DOI - PMC - PubMed
    1. Liu W.J. On the ground in Western Africa: from the outbreak to the elapse of Ebola. Protein Cell. 2016;7:621–623. doi: 10.1007/s13238-016-0305-2. - DOI - PMC - PubMed
    1. Morel C.M., Acharya T., Broun D., Dangi A., Elias C., Ganguly N.K., Gardner C.A., Gupta R.K., Haycock J., Heher A.D., Hotez P.J., Kettler H.E., Keusch G.T., Krattiger A.F., Kreutz F.T., Lall S., Lee K., Mahoney R., Martinez-Palomo A., Mashelkar R.A., Matlin S.A., Mzimba M., Oehler J., Ridley R.G., Senanayake P., Singer P., Yun M. Health innovation networks to help developing countries address neglected diseases. Science. 2005;309:401–404. doi: 10.1126/science.1115538. - DOI - PubMed
    1. Butler D., Celina M. Turchi: Zika detective. Nat. News. 2016;540:507. doi: 10.1038/540507a. - DOI
    1. Fintelman-Rodrigues N., Sacramento C.Q., Lima C.R., da Silva F.S., Ferreira A.C., Mattos M., de Freitas C.S., Soares V.C., da Dias S.G., Temerozo J.R., Miranda M.D., Matos A.R., Bozza F.A., Carels N., Alves C.R., Siqueira M.M., Bozza P.T., Souza T.M.L. Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production. Antimicrob. Agents Chemother. 2020;64 doi: 10.1128/AAC.00825-20. - DOI - PMC - PubMed